Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
40%
Ph phase_2
3
60%

Phase Distribution

0

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (60.0%)
Phase 32 (40.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_3

Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients

NCT01093196
completedphase_3

Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma

NCT01090089
completedphase_2

Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome

NCT01816620
completedphase_2

Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL)

NCT01459211
completedphase_2

Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia

NCT01553357

Clinical Trials (5)

Showing 5 of 5 trials
NCT01093196Phase 3

Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients

Completed
NCT01090089Phase 3

Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma

Completed
NCT01816620Phase 2

Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome

Completed
NCT01459211Phase 2

Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL)

Completed
NCT01553357Phase 2

Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5